MedTrace Logo

Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage

NCT02866877 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2024-04-02

No results posted yet for this study

Summary

This study evaluates the pharmacokinetic profile of levetiracetam in critically ill patients who have suffered a subarachnoid hemorrhage. The patients will be evaluated for development of augmented renal clearance and the effects and duration of effects this may have on levetiracetam clearance.

Conditions

  • Subarachnoid Hemorrhage

Interventions

OTHER

Pharmacokinetic modeling

Timed blood draws and urine collections to model drug clearance

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Edward T Van Matre, PharmD · University of Colorado School of Pharmacy

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2019-06-30
Completion
2021-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02866877 on ClinicalTrials.gov